Urology
Volume 75, Issue 5 , Page 1143 , May 2010

Editorial Comment

References 

  1. Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009;24(suppl 2):389–394
  2. Mincey BA, Tan WW. The management of bone loss in patients with breast or prostate cancer. Support Cancer Ther. 2004;1:150–156
  3. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen deprivation therapy for prostate cancer. N Engl Med. 2001;345:948–955
  4. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zolendronic acid to prevent bone loss in men receiving androgen deprivation for nonmetastatic prostate cancer. J Urol. 2003;169:2008–2012
  5. Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. North Engl Edn Med. 2009;361:745–755

PII: S0090-4295(10)00044-0

doi: 10.1016/j.urology.2009.12.055

Urology
Volume 75, Issue 5 , Page 1143 , May 2010

Article Tools